经与会董事审议，以投票表决的方式通过了以下议案： 证券代码：300846 证券简称：首都在线 公告编号：2025-060 北京首都在线科技股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、会议召开情况 （一）审议通过了《关于为全资子公司提供担保的议案》 北京首都在线科技股份有限公司（以下简称"公司"）第六届董事会第六次会议于 2025 年 6 月 10 日在公司会议室以现场与通讯相结合的方式召开。会议通知于 2025 年 6 月9日以邮件方式送达各位董事，各位董事确认收悉。会议由公司董事长曲宁先生主持， 应出席董事 7 人，实际出席董事 7 人，公司全体监事和高级管理人员列席了会议。会议 的召开符合《中华人民共和国公司法》（以下简称"《公司法》"）《北京首都在线科 技股份有限公司章程》（以下简称"《公司章程》"）和《北京首都在线科技股份有限 公司董事会议事规则》的有关规定。 二、会议表决情况 为支持全资子公司的经营发展，公司董事会同意为子公司提供担保。前述事项有利 于促进其经营发展、提升其经营效率和盈利能力。 董事会 ...

Market Overview - The Shanghai Composite Index closed at 3393.26 points, above the six-month moving average, with a change of 0.23% [1] - The total trading volume of A-shares reached 838.618 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 184 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 11.69% deviation, closing price 14.38 yuan, with a daily increase of 20.03% and turnover rate of 15.50% [1] - Haochen Medical: 8.62% deviation, closing price 3.12 yuan, with a daily increase of 9.86% and turnover rate of 6.44% [1] - Jinyinhai: 7.58% deviation, closing price 21.00 yuan, with a daily increase of 9.66% and turnover rate of 6.43% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Guangyun Technology: 7.45% deviation, closing price 14.13 yuan, with a daily increase of 9.20% and turnover rate of 4.78% [1] - Yaowang Technology: 5.93% deviation, closing price 7.12 yuan, with a daily increase of 7.88% and turnover rate of 13.64% [1] - Nuotai Biotech: 5.91% deviation, closing price 55.37 yuan, with a daily increase of 10.36% and turnover rate of 5.58% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month moving average include: - Guangdong Hongtu: just above the six-month line [1] - Xinhe Shares: just above the six-month line [1] - Songjing Shares: just above the six-month line [1]

Core Insights - The National Medical Products Administration approved 11 innovative drugs recently, with 10 coming from listed companies, indicating a significant advancement in China's pharmaceutical sector [1][4] - The approval of these drugs marks a pivotal moment for the industry, as it transitions into a phase of realizing the results of extensive research and development efforts [7][8] Group 1: Drug Approvals and Innovations - Among the approved drugs, several are the first of their kind in China, including Bai Jie Shen Zhou's injection of Zhenida Monoclonal Antibody, which is the first HER2 dual-target drug approved for cholangiocarcinoma [4][5] - Heng Rui Pharmaceutical's Apixaban is a multi-target tyrosine kinase inhibitor approved for use in advanced solid tumors, showcasing innovative treatment mechanisms [4][5] - The approval of Zai Jing Pharmaceutical's Jikaxitinib marks the first domestic JAK inhibitor for treating myelofibrosis, providing new options for patients with rare blood cancers [5][6] Group 2: Market Trends and Investment Opportunities - The innovative drug sector has seen a strong market performance, with 53 stocks hitting the daily limit up, indicating heightened investor interest [2][7] - Analysts predict that 2025 will be a transformative year for the pharmaceutical industry, characterized by increased revenue, profitability, and valuation improvements [1][7] - The Hong Kong innovation drug index has seen significant capital inflow, with over 200 million yuan in net inflow over the past 20 trading days, reflecting strong market sentiment [2][8] Group 3: Challenges and Future Outlook - Despite the positive developments, the innovative drug industry faces challenges such as high uncertainty in commercialization and intense competition among similar products [7][8] - The industry is supported by favorable policies and the growth of commercial health insurance, which enhances the payment environment for innovative drugs [8]

Core Insights - The rapid expansion of AI computing power in China is highlighted, with the current capacity reaching 3000P for training and 1000P for inference, and over 250 innovative solutions developed across various sectors [1] - The integration of computing power and network technology, referred to as "算网融合" (computing-network integration), is identified as a critical path for addressing the growing demand for AI computing resources and enhancing computational efficiency [3][6] - The Chinese intelligent computing power market is projected to grow significantly, with estimates indicating a market size of $25.9 billion by 2025, reflecting a 36.2% increase from 2024 [2] Industry Growth and Trends - The intelligent computing power scale in China is expected to reach 1037.3 EFLOPS by 2025, representing a 43% increase from 2024, and is projected to double by 2026 [2] - The compound annual growth rate (CAGR) for China's intelligent computing scale from 2023 to 2028 is forecasted at 46.2%, indicating a strong trend towards large and super-large intelligent computing centers [2] - The demand for AI models is driving a significant increase in computing power requirements, with current needs exceeding hardware supply by over 200 times [3] Technological Developments - Companies are focusing on transforming data centers into intelligent computing centers, emphasizing the need for efficient, green, and high-performance solutions [4][5] - Huawei is leveraging advanced technologies such as zero-loss networking and intelligent computing network scheduling to enhance computing resource utilization from 40% to 75% [5] - The integration of distributed computing architecture, low-latency networks, and virtualization technologies is essential for achieving high-quality development in computing power [6] Market Dynamics - The competition among enterprises for intelligent computing resources is intensifying, with a focus on optimizing computing infrastructure and enhancing service capabilities [5] - The shift from hardware-centric approaches to efficiency-driven models in AI computing is becoming evident, necessitating a demand-oriented and benefit-oriented approach in intelligent computing center construction [6]

证券代码：300846 证券简称：首都在线 公告编号：2025-059 北京首都在线科技股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 北京首都在线科技股份有限公司（以下简称"公司"）财务人员于近日通过 查询银行账户获悉，公司募集资金专项账户的资金被北京市朝阳区人民法院冻结 一、本次部分募集资金专项账户的部分资金被冻结基本情况 | | | | 截至 | 2025 年 5 | | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 月 27 | 账户性质 | 本次被冻结 | | 户名 | 开户银行 | 银行账号 | | | | | | | | | | 日账户余额 | | 金额（元） | | | | | | （元） | | | | | 中国民生银 | | | | | | | 北京首都在 | | | | | | | | | 行股份有限 | | | | 募集资金 | | | 线科技股份 | | 644397265 | | 311,002,440.96 | | 6,224,699.02 | | | 公 ...

证券代码：300846 证券简称：首都在线 公告编号：2025-059 截至本公告披露日，公司尚未收到法院关于本次冻结公司银行账户的法律 文书、通知或其他信息。经公司初步自查了解，本次募集资金专项账户部分资 金被冻结系因公司与北京天翔睿翼科技有限公司（以下简称"天翔睿翼"）之 间的合同纠纷。公司与天翔睿翼互为供应商和客户关系，双方在合同履行过程 中就各自应收款项支付问题存在争议，未能协商一致，公司已就天翔睿翼欠款 另案申请仲裁，而此次资金冻结是由于天翔睿翼向法院提起诉讼并申请财产保 全所导致，最终冻结公司资金 6,224,699.02 元。 截至本公告披露日，上述涉及财产保全的案件处于诉前调解阶段，公司尚 1 户名 开户银行 银行账号 截至 2025 年 5 月 27 日账户余额 （元） 账户性质 本次被冻结 金额（元） 北京首都在 线科技股份 有限公司 中国民生银 行股份有限 公司北京陶 然桥支行 644397265 311,002,440.96 募集资金 专项账户 6,224,699.02 一、本次部分募集资金专项账户的部分资金被冻结基本情况 未收到法院送达的上述案件相关的其他正式法律文书。 三、本次部分 ...

Fundraising Overview - The company raised a total of RMB 715 million by issuing 55 million shares at RMB 13.00 per share, with a net amount of RMB 699.14 million after deducting issuance costs of RMB 215.86 million [1] - The funds are managed in accordance with the company's fundraising management system and relevant regulations to protect investor interests [1] Fundraising Account Details - The company has opened fundraising accounts at several banks, including Shanghai Pudong Development Bank, China Minsheng Bank, and Ningbo Bank, for the management of the raised funds [2] - The company has also established accounts for its new investment project entities, including Intercity Connect (USA) Co., Ltd. and Gansu Shouyun Zhican Technology Co., Ltd. [2][3] Account Cancellation - The company has completed the cancellation of a fundraising account at China Minsheng Bank, which will no longer be used, and the corresponding tripartite supervision agreement has been terminated [3][4] - The cancellation of this account does not affect other fundraising investment projects and does not change the intended use of the funds or harm shareholder interests [4]

证券代码：300846 证券简称：首都在线 公告编号：2025-058 北京首都在线科技股份有限公司 截至本公告披露日,公司2021年度向特定对象发行股票募集资金的专用账户 情况如下： | 序 | 账户名称 | 开户银行 | 专户账号 | 募集资金投资项 | 账户状态 | | --- | --- | --- | --- | --- | --- | | 号 | | | | 目 | | | | 北京首都在线科 | 上海浦东发展银 行股份有限公司 | 9119007880 | 一体化云服务平 | | | 1 | | | | | 存续 | | | 技股份有限公司 | 北京东长安街支 | 1100001830 | 台升级项目 | | | | | 行 | | | | | | 北京首都在线科 | 中国民生银行股 | | 弹性裸金属平台 | | | 2 | 技股份有限公司 | 份有限公司北京 | 634149106 | 建设项目 | 本次注销 | | | | 陶然桥支行 | | | | | 3 | 北京首都在线科 | 宁波银行股份有 | 7701012200 | 募集资金归集及 | 已注销 | | | 技股份有限公司 | 限 ...

证券代码：300846 证券简称：首都在线 公告编号：2025-056 邮件方式向全体监事发出第六届监事会第五次会议通知。 称"《公司法》"） 《北京首都在线科技股份有限公司章程》 （以下简称"《公司章程》"） 和《北京首都在线科技股份有限公司监事会议事规则》等有关规定，会议程序和结果合 法有效。 二、监事会会议审议情况 经与会监事审议，以投票表决的方式审议通过了《关于使用部分闲置募集资金暂 时补充流动资金的议案》。 北京首都在线科技股份有限公司 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开和出席情况 表决结果：3 票同意；0 票反对；0 票弃权。本议案获得通过。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《关于使用部 分闲置募集资金暂时补充流动资金的公告》。 三、备查文件 《北京首都在线科技股份有限公司第六届监事会第五次会议决议》。 特此公告。 北京首都在线科技股份有限公司 监事会 监事会认为在保证募投项目建设的资金需求及募投项目正常进行的前提下，结合公 司生产经营需求及财务情况，公司使用闲置募集资金 3 ...

二、募集资金使用情况 中信证券股份有限公司 关于北京首都在线科技股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为北京首 都在线科技股份有限公司（以下简称"首都在线"、"公司"）的持续督导机构， 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有 关规定，对公司本次使用部分闲置募集资金暂时补充流动资金的事项发表核查意 见如下： 一、募集资金基本情况 根据中国证监会的《关于同意北京首都在线科技股份有限公司向特定对象发 行股票注册的批复》（证监许可[2023]2918 号），公司向特定对象发行人民币普通 股（A 股）33,639,314 股，发行价格为人民币 10.50 元/股，募集资金总额为人民 币 353,212,797.00 元，扣除各项发行费用（不含增值税）人民币 10,546,338.01 元后，募集资金净额为人民币 342,666,458.99 元。2024 ...